Appendix 4C Financial Report
BRISBANE & MELBOURNE, 25 July, 2019
Anatara Lifesciences is pleased to release its Appendix 4C financial report for the quarter ending 30th June 2019. The Company's cash plus term deposits at the end of the quarter stood at $5.4m. Expenditure during the quarter was in line with forecast.
Forecast expenditure for the September 2019 quarter is anticipated to increase as research and development activities for the Company’s lead human health program, its Gastrointestinal Reprogramming (GaRP) dietary supplement, advances. Future quarterly gross cash outflow is anticipated to decline to an average of $1.2m for the remaining quarters of the 2020 financial year.
Please click here to view the ASX announcement.
|
